Luye Pharma Group Ltd.
LYPHFOTCHealthcare● Active
$0.40
+$0.07(+20.50%)
Market Cap$1.6B
P/E Ratio—
52W High$0.395
52W Low$0.268
Luye Pharma Group Ltd. (LYPHF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LYPHF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 29, 2026EPS Actual
$0.01
Est. $0.01 · +0.0%
Revenue
$0.45B
Est. $0.49B · -9.5%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 29, 2026
After Market Close
▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
LYPHF reports quarterly as a OTC-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.01B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 27, 2026 | $0.01 | — | — | — | $0.47B | — |
| — Q1 FY2026 | Mar 29, 2026 | $0.01 | $0.01 | +0.0% | $0.45B | $0.49B | -9.5% |
| ▲ Q3 FY2025 | Aug 28, 2025 | $0.01 | $0.01 | +18.8% | $0.44B | $0.42B | +5.3% |
| ▼ Q1 FY2025 | Mar 27, 2025 | $0.02 | $0.00 | -79.7% | $0.41B | $0.47B | -13.6% |
| — Q3 FY2024 | Aug 28, 2024 | — | $0.01 | — | $0.42B | — | — |
| ▲ Q2 FY2024 | Apr 8, 2024 | $0.01 | $0.01 | +1.9% | $0.46B | $0.45B | +2.0% |
| ▲ Q2 FY2023 | Jun 30, 2023 | $0.00 | $0.01 | +35.3% | $0.40B | $0.41B | -2.3% |
| ▲ Q1 FY2023 | Mar 29, 2023 | $0.01 | $0.01 | +48.5% | $0.46B | $0.43B | +5.4% |
Q3 FY2026
Aug 27, 2026
EPS Actual
—
EPS Est.
$0.01
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 29, 2026
EPS Actual
$0.01
EPS Est.
$0.01
EPS Surpr.
+0.0%
Revenue
$0.45B
Q3 FY2025
Aug 28, 2025Beat
EPS Actual
$0.01
EPS Est.
$0.01
EPS Surpr.
+18.8%
Revenue
$0.44B
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
$0.00
EPS Est.
$0.02
EPS Surpr.
-79.7%
Revenue
$0.41B
Q3 FY2024
Aug 28, 2024
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.42B
Q2 FY2024
Apr 8, 2024Beat
EPS Actual
$0.01
EPS Est.
$0.01
EPS Surpr.
+1.9%
Revenue
$0.46B
Q2 FY2023
Jun 30, 2023Beat
EPS Actual
$0.01
EPS Est.
$0.00
EPS Surpr.
+35.3%
Revenue
$0.40B
Q1 FY2023
Mar 29, 2023Beat
EPS Actual
$0.01
EPS Est.
$0.01
EPS Surpr.
+48.5%
Revenue
$0.46B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.08 | $0.08 | $0.08 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.07 | $0.07 | $0.07 | 1 |
| Q2 FY2024 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2023 | $0.10 | $0.10 | $0.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $23.5B | $23.5B | $23.5B | 1 |
| Q3 FY2025 | $3.2B | $3.2B | $3.2B | 1 |
| Q2 FY2025 | $21.7B | $21.7B | $21.7B | 1 |
| Q2 FY2024 | $3.1B | $3.1B | $3.1B | 1 |
| Q4 FY2023 | $22.5B | $22.5B | $22.5B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 29, 2026 | +0.0% | $0.38 | $0.38 | +0.00% |
| ▲ Q3 FY2025 | Aug 28, 2025 | +18.8% | $0.27 | $0.27 | +0.00% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -79.7% | $0.26 | $0.26 | +0.00% |
| — Q3 FY2024 | Aug 28, 2024 | — | $0.37 | $0.31 | -16.38% |
| ▲ Q2 FY2024 | Apr 8, 2024 | +1.9% | $0.39 | $0.37 | -4.21% |
| ▲ Q2 FY2023 | Jun 30, 2023 | +35.3% | $0.47 | $0.47 | +0.00% |
| ▲ Q1 FY2023 | Mar 29, 2023 | +48.5% | $0.75 | $0.75 | +0.00% |
| ▼ Q3 FY2022 | Aug 29, 2022 | -34.3% | $0.75 | $0.75 | +0.00% |
Q1 FY2026+0.00%
Report Date
Mar 29, 2026
EPS Beat/Miss
+0.0%
Price Before
$0.38
Price After
$0.38
Q3 FY2025+0.00%
Report Date
Aug 28, 2025
EPS Beat/Miss
+18.8%
Price Before
$0.27
Price After
$0.27
Q1 FY2025+0.00%
Report Date
Mar 27, 2025
EPS Beat/Miss
-79.7%
Price Before
$0.26
Price After
$0.26
Q3 FY2024-16.38%
Report Date
Aug 28, 2024
EPS Beat/Miss
—
Price Before
$0.37
Price After
$0.31
Q2 FY2024-4.21%
Report Date
Apr 8, 2024
EPS Beat/Miss
+1.9%
Price Before
$0.39
Price After
$0.37
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
+35.3%
Price Before
$0.47
Price After
$0.47
Q1 FY2023+0.00%
Report Date
Mar 29, 2023
EPS Beat/Miss
+48.5%
Price Before
$0.75
Price After
$0.75
Q3 FY2022+0.00%
Report Date
Aug 29, 2022
EPS Beat/Miss
-34.3%
Price Before
$0.75
Price After
$0.75
Avg Beat Reaction-0.84%
Avg Miss Reaction+0.00%
Beat Rate5 / 8 quarters
Largest Move-16.38% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LYPHF ends December
Luye Pharma Group Ltd. (LYPHF) most recently reported earnings on March 29, 2026 for Q1 FY2026, posting EPS of $0.01 (in line with the analyst consensus of $0.01). LYPHF has beaten EPS estimates for 2 consecutive quarters. The next LYPHF earnings date is expected around September 1, 2026.
Each quarter, investors track LYPHF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LYPHF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LYPHF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LYPHF earnings · 4 questionsLuye Pharma Group Ltd.'s next earnings report is expected around September 1, 2026. LYPHF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LYPHF historically reports after market close (AMC).
LYPHF earnings datewhen is LYPHF earningsLYPHF next earnings datewhen does LYPHF report earningsLYPHF earnings calendar
▸ Source: FMP · Luye Pharma Group Ltd. SEC filings · US GAAP · Luye Pharma Group Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026